LyondellBasell
LYB
$70.72
-1.78%
LyondellBasell Industries N.V. is a global petrochemical producer, operating primarily in the United States, Europe, and Asia, within the specialty chemicals industry. The company is a market leader, holding the title of the world's largest producer of polypropylene and a major producer of polyethylene and propylene oxide. The current investor narrative is dominated by the severe cyclical downturn in the chemical industry, evidenced by recent financial losses and a significant dividend cut, juxtaposed against a recent sharp stock price rally driven by geopolitical de-escalation and easing input cost pressures.…
LYB
LyondellBasell
$70.72
Related headlines
Investment Opinion: Should I buy LYB Today?
Rating: Hold. The core thesis is that LYB is a deeply cyclical stock at a potential inflection point, where the compelling valuation discount is counterbalanced by severe near-term fundamental headwinds, warranting a cautious stance pending clearer signs of recovery.
The stock trades at a deeply discounted Price-to-Sales ratio of 0.46, which is near the bottom of its historical range and suggests significant embedded recovery potential. However, this discount is justified by collapsing profitability, with a trailing net margin of -2.46% and a forward PE of 12.25 based on estimated EPS of $5.64. The powerful 6-month price rally of 43.47% and robust TTM FCF of $2.26B are positive, but these are offset by the recent -11.88% monthly pullback and the Q4 revenue decline of 25.3% YoY. Analyst sentiment is mixed but shifting cautiously, with recent upgrades from Citigroup and RBC.
The thesis would upgrade to a Buy if LYB demonstrates two consecutive quarters of sequential margin improvement (e.g., gross margin recovering above 10%) or if the stock pulls back to the $50-$55 range, offering a larger margin of safety. It would downgrade to a Sell if quarterly losses widen sequentially or if revenue decline accelerates beyond 30% YoY. Based on current data, the stock appears fairly valued relative to its deeply cyclical risk profile—it is not overpriced for a recovery bet, but the recovery is not yet assured.
Sign up to view all
LYB 12-Month Price Forecast
LYB presents a high-risk, high-reward proposition typical of deep cyclicals. The valuation is compelling for patient investors, but the timing of the recovery is highly uncertain. The recent price surge has likely front-run the fundamentals, leading to the current consolidation. The stance is neutral, as the stock needs to either demonstrate fundamental progress or trade at a more attractive entry point to justify a bullish view. An upgrade to bullish would require concrete evidence of margin stabilization in the next earnings report. A downgrade to bearish would be triggered by a breakdown below key technical support near $60, signaling the failure of the recovery narrative.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on LyondellBasell's 12-month outlook, with a consensus price target around $91.94 and implied upside of +30.0% versus the current price.
Average Target
$91.94
10 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
10
covering this stock
Price Range
$57 - $92
Analyst target range
Analyst coverage consists of 10 firms, with recent institutional ratings showing a mix of upgrades, downgrades, and holds, reflecting high uncertainty; the consensus leans neutral, as evidenced by recent actions from Wells Fargo (Equal Weight), Mizuho (Neutral), and Deutsche Bank (Hold). The average target price and implied upside are not provided in the data, but the wide range of recent analyst actions—including Citigroup upgrading to Buy, RBC Capital moving to Outperform, and BMO Capital upgrading to Market Perform—signals a shifting sentiment from bearish to cautiously optimistic, likely in response to the stock's technical breakout and easing geopolitical risks. The absence of a specific consensus target price suggests limited or conflicting forward guidance, which is typical for a cyclical stock at an inflection point, leading to higher volatility and price discovery driven by macro and commodity factors rather than earnings estimates.
Bulls vs Bears: LYB Investment Factors
The investment debate for LYB is a classic battle between deep cyclical value and near-term operational distress. The bull case, currently supported by stronger evidence from the powerful price recovery and extreme valuation discount, hinges on the belief that the stock has already priced in a worst-case scenario and that an industry inflection is imminent. The bear case is grounded in the harsh reality of collapsing revenues, negative earnings, and a recent dividend cut. The single most important tension is the timing of the chemical cycle recovery. If input cost relief translates to margin stabilization in the next 1-2 quarters, the bulls will be validated. If the downturn persists longer than expected, pressuring cash flow further, the bearish fundamentals will reassert dominance.
Bullish
- Deep Cyclical Valuation Discount: The stock trades at a trailing PS ratio of 0.46, near the absolute bottom of its historical range and deeply discounted compared to typical chemical industry averages. This pricing reflects peak pessimism, offering significant upside potential if the industry cycle inflects, as the market cap of $23.8B is valued at a fraction of its sales.
- Despite operating losses, the company generated $2.26 billion in trailing twelve-month free cash flow. This robust cash generation provides a crucial buffer to navigate the downturn, supports capital expenditures, and underpins the sustainability of its reduced dividend.
- Powerful Technical Recovery Trend: The stock has surged 43.47% over the past six months, decisively breaking a longer-term downtrend. This technical breakout, from a 52-week low of $41.58 to a recent high of $83.94, signals a major shift in market sentiment and momentum.
- Improving Sequential Losses: The Q4 2025 net loss of $140 million is a significant improvement from the $892 million loss in Q3 2025. This sequential improvement, while still negative, suggests the cyclical trough may be bottoming, with the worst of the margin compression potentially behind the company.
Bearish
- Severe Cyclical Downturn in Progress: Q4 2025 revenue declined 25.33% year-over-year to $7.09B, continuing a multi-quarter downtrend. The company reported a full-year net loss with a negative net margin of -2.46%, confirming it is in the depths of a severe industry downcycle.
- Collapsing Profitability and Margins: Gross margin collapsed to 6.49% in Q4 2025, down from 7.90% a year earlier and a peak of 16.5% in Q2 2024. The trailing twelve-month operating margin is -1.08%, indicating the core business is currently unprofitable.
- Recent Sharp Momentum Reversal: The stock is down 11.88% over the past month, including a sharp 11.98% single-day drop on April 17th. This divergence from the longer-term uptrend signals a significant pullback from overbought conditions and potential failure at resistance near $84.
- Dividend Cut Signals Deep Stress: The company recently slashed its dividend, a move described as a response to 'one of the longest downturns in the chemical industry.' This action directly reduces income for shareholders and signals management's expectation of prolonged cash flow challenges.
LYB Technical Analysis
The stock is in a powerful recovery trend, having surged 43.47% over the past six months and 30.17% over the last three months, decisively reversing a longer-term downtrend. With a current price of $66.27, it is trading at approximately 79% of its 52-week range ($41.58 to $83.94), indicating it has recovered significantly from lows but remains below recent highs, suggesting room for further momentum or potential resistance. Recent momentum, however, shows a stark divergence, with the stock down 11.88% over the past month, including a sharp 11.98% single-day drop, signaling a significant pullback from overbought conditions and a potential consolidation phase after the parabolic rise from March. Key technical support is anchored at the 52-week low of $41.58, while immediate resistance is at the recent high near $83.94; a sustained breakdown below the recent low of $66.27 could signal a deeper correction, while a breakout above $84 would confirm the resumption of the uptrend. The stock's beta of 0.437 indicates it is significantly less volatile than the broader market, which, combined with a 1-month relative strength of -19.24%, suggests it has recently acted as a defensive laggard during the market's rally.
Beta
0.44
0.44x market volatility
Max Drawdown
-42.6%
Largest decline past year
52-Week Range
$42-$84
Price range past year
Annual Return
+22.4%
Cumulative gain past year
| Period | LYB Return | S&P 500 |
|---|---|---|
| 1m | -7.0% | +8.5% |
| 3m | +38.7% | +2.8% |
| 6m | +48.6% | +4.6% |
| 1y | +22.4% | +32.3% |
| ytd | +59.3% | +3.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LYB Fundamental Analysis
Revenue is under significant pressure, with Q4 2025 sales of $7.09 billion reflecting a steep 25.33% year-over-year decline, continuing a multi-quarter downtrend from $9.50 billion in Q4 2024, indicating the company is in the midst of a severe industry downcycle. Profitability has deteriorated sharply, with the company reporting a net loss of $140 million in Q4 2025 and a gross margin of just 6.49%, down from 7.90% a year earlier; the full-year EPS of -$0.053 and negative net margin of -2.46% highlight the depth of the cyclical trough, though the Q4 loss is an improvement from the $892 million loss in Q3 2025. The balance sheet shows a leveraged but cash-generative position, with a debt-to-equity ratio of 1.58 and a current ratio of 1.77, while trailing twelve-month free cash flow of $2.26 billion provides a crucial buffer, supporting the recent dividend payment and capital expenditures despite the operating losses.
Quarterly Revenue
$7.1B
2025-12
Revenue YoY Growth
-0.25%
YoY Comparison
Gross Margin
+0.06%
Latest Quarter
Free Cash Flow
$2.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LYB Overvalued?
Given the negative net income, the primary valuation metric is the Price-to-Sales (PS) ratio. The trailing PS ratio is 0.46, while the forward-looking metric is the EV/Sales of 1.18, indicating the market is valuing the company's sales at a significant discount on a price basis but at a more standard multiple on an enterprise value basis. Compared to typical chemical industry averages, a PS ratio of 0.46 is deeply discounted, reflecting the market's severe pessimism regarding current margins and the cyclical downturn, though this discount may be justified by the company's current lack of profitability and compressed gross margins of 9.00%. Historically, the stock's current PS ratio of 0.46 is near the absolute bottom of its multi-year range, which has extended above 4.0 during peak cycles; this positioning suggests the stock is pricing in a worst-case scenario, offering a potential value opportunity if the chemical cycle shows signs of inflection.
PE
-18.8x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -25x~42x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
22.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and immediate. The company is operating at a loss, with a Q4 2025 net loss of $140 million and a gross margin of just 6.49%. Revenue has fallen 25.3% YoY, indicating deep cyclical pressure. While strong TTM FCF of $2.26B provides a buffer, the recent dividend cut signals management is conserving cash, and the debt-to-equity ratio of 1.58 adds fixed-cost pressure in a downturn. The primary risk is that the industry trough is deeper or longer than anticipated, leading to sustained losses that erode the balance sheet.
Market & Competitive Risks center on valuation compression and macro sensitivity. Although the PS ratio of 0.46 is deeply discounted, it could remain depressed or contract further if the cycle fails to turn. The stock's low beta of 0.437 suggests it is less volatile than the market, but its recent -19.24% 1-month relative strength shows it can sharply underperform during specific market phases (e.g., a 'peace trade' rally). Competitive risks are heightened as all players fight for volume in a shrinking market, potentially delaying margin recovery. Regulatory and environmental costs also pose a persistent headwind.
Worst-Case Scenario involves a prolonged global recession that extends the chemical industry downturn for multiple years. This would lead to consecutive quarterly losses, a breach of debt covenants, a suspension of the remaining dividend, and a forced equity raise at depressed prices. In this scenario, the stock could realistically revisit its 52-week low of $41.58, representing a downside of approximately -37% from the current price of $66.27. The historical max drawdown of -43.74% provides a precedent for such severe losses during cyclical lows.
FAQ
The key risks are, in order of severity: 1) Cyclical Downturn Risk: The chemical industry remains in a severe downcycle, with LYB's Q4 revenue down 25.3% YoY and gross margin at 6.49%. A prolonged slump is the primary threat. 2) Financial Risk: Leverage with a debt-to-equity ratio of 1.58 amplifies losses and could pressure the balance sheet if losses persist. 3) Commodity Price Risk: Input cost volatility (e.g., naphtha) can swiftly erase margin improvements, as seen in recent news-driven price swings. 4) Execution Risk: The company's ability to manage costs and navigate the downturn while investing for the future is critical but uncertain.
The 12-month forecast is highly bifurcated, with a base case target range of $65-$75 (50% probability), a bull case of $83-$95 (30% probability), and a bear case of $42-$55 (20% probability). The base case, which is most likely, assumes a slow, volatile recovery where the stock oscillates as the company gradually returns to profitability. The forecast hinges almost entirely on the trajectory of chemical spreads and gross margins. The key assumption is that the cycle has bottomed, but the slope of the recovery remains shallow, preventing a swift re-rating to peak multiples.
LYB is deeply undervalued on a historical and relative sales basis, trading at a Price-to-Sales ratio of 0.46, which is near the bottom of its multi-year range. However, this discount is rational given its current lack of profitability, with a negative net margin and trailing EPS of -$0.053. The forward PE of 12.25, based on analyst estimates, suggests the market is pricing in a recovery. The valuation implies the market expects a cyclical rebound but remains skeptical about its timing and magnitude. It is fairly valued for the high risk involved, not cheap for a high-quality business.
LYB is a speculative buy for investors with a high risk tolerance and a long-term horizon who are betting on a chemical cycle recovery. At a PS ratio of 0.46, it is priced for distress, offering significant upside if the cycle turns. However, it is not a 'good buy' for all investors, given its recent net losses, dividend cut, and -11.88% pullback over the past month. The most compelling case is for value-oriented, contrarian portfolios willing to endure volatility. Conservative investors should wait for more concrete evidence of margin recovery before considering a position.
LYB is strictly a long-term investment for a minimum holding period of 3-5 years to fully capture a potential chemical cycle upswing. Its low beta of 0.437 and cyclical nature make it a poor short-term trading vehicle, as prices can be range-bound for quarters despite large underlying moves. The recent dividend cut also removes it as an income play. It is suitable only for the cyclical portion of a diversified portfolio where an investor can be patient through volatility. Short-term traders should avoid it due to its fundamental-driven, rather than momentum-driven, price action.